Literature DB >> 33574667

Pterostilbene Nanoparticles Downregulate Hypoxia-Inducible Factors in Hepatoma Cells Under Hypoxic Conditions.

Wen-Sheng Tzeng1,2, Wei-Lin Teng3, Pao-Hsien Huang4, Tzu-Ching Lin3, Feng-Lin Yen2,5,6,7, Yow-Ling Shiue2.   

Abstract

PURPOSE: Transcatheter arterial chemoembolization (TACE) is a common clinical treatment for hepatocellular carcinoma (HCC). However, hypoxia induction after treatment might trigger tumor invasiveness and metastasis. Although pterostilbene (PTS) has antitumor effects, its chemoprevention in HepG2 cells under hypoxia has not been investigated yet. In addition, the poor water solubility of raw PTS limits its clinical application. Here, we prepared nanoparticles of PTS (PSN) and compared their antihepatoma activities with those of raw PTS in HepG2 under hypoxic conditions.
MATERIALS AND METHODS: The PTS nanoparticle formulation was prepared by nanoprecipitation, using Eudragit® e100 (EE) and polyvinyl alcohol (PVA) as carriers. We analyzed the physicochemical properties of raw PTS and PSN, including yield, encapsulation efficiency, water-solubility, particle size, morphology, crystalline-to-amorphous transformation, and molecular interaction between PTS and carriers. We also evaluated their antihepatoma activities under hypoxia treatment in HepG2 cells, including cell viability, hypoxia, and apoptosis.
RESULTS: The yield and encapsulation efficiency of PSN were 86.33% and >99%, respectively. The water solubility and drug release of PTS were effectively improved after nanoprecipitation corresponding to the reduction in particle size, amorphous transformation, and formation of hydrogen bonding with carriers. PSN had a better cytotoxic effect than raw PTS in HepG2 under pre- and post-hypoxia conditions. In addition, hypoxia- and apoptosis-related proteins in HepG2 cells under two different hypoxic conditions were significantly inhibited by PSN compared with the control group with hypoxia only, except for HIF-1α in the post-hypoxia group. PSN was also significantly better in inhibiting these proteins, except for Bcl2, under pre-hypoxic conditions.
CONCLUSION: Our results suggested that PSN could improve the water solubility and drug release of PTS and enhance the efficacy of HCC treatment under hypoxic conditions.
© 2021 Tzeng et al.

Entities:  

Keywords:  hepatocellular carcinoma; hypoxia; transcatheter arterial chemoembolization

Mesh:

Substances:

Year:  2021        PMID: 33574667      PMCID: PMC7873716          DOI: 10.2147/IJN.S282172

Source DB:  PubMed          Journal:  Int J Nanomedicine        ISSN: 1176-9114


  47 in total

Review 1.  Pterostilbene: Biomedical applications.

Authors:  José M Estrela; Angel Ortega; Salvador Mena; Maria L Rodriguez; Miguel Asensi
Journal:  Crit Rev Clin Lab Sci       Date:  2013-07-01       Impact factor: 6.250

2.  Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.

Authors:  Matthias Pinter; Florian Hucke; Ivo Graziadei; Wolfgang Vogel; Andreas Maieron; Robert Königsberg; Rudolf Stauber; Birgit Grünberger; Christian Müller; Claus Kölblinger; Markus Peck-Radosavljevic; Wolfgang Sieghart
Journal:  Radiology       Date:  2012-03-21       Impact factor: 11.105

3.  Pterostilbene inhibits hepatocellular carcinoma through p53/SOD2/ROS-mediated mitochondrial apoptosis.

Authors:  Liying Guo; Kai Tan; Hao Wang; Xuan Zhang
Journal:  Oncol Rep       Date:  2016-10-05       Impact factor: 3.906

4.  Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization.

Authors:  B Wang; H Xu; Z Q Gao; H F Ning; Y Q Sun; G W Cao
Journal:  Acta Radiol       Date:  2008-06       Impact factor: 1.990

Review 5.  Polymer-based nanocapsules for drug delivery.

Authors:  C E Mora-Huertas; H Fessi; A Elaissari
Journal:  Int J Pharm       Date:  2009-10-13       Impact factor: 5.875

6.  Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.

Authors:  Riccardo Lencioni; Josep M Llovet; Guohong Han; Won Young Tak; Jiamei Yang; Alfredo Guglielmi; Seung Woon Paik; Maria Reig; Do Young Kim; Gar-Yang Chau; Angelo Luca; Luis Ruiz Del Arbol; Marie-Aude Leberre; Woody Niu; Kate Nicholson; Gerold Meinhardt; Jordi Bruix
Journal:  J Hepatol       Date:  2016-01-22       Impact factor: 25.083

7.  Hypoxia-Induced Caveolin-1 Expression Promotes Migration and Invasion of Tumor Cells.

Authors:  J Castillo Bennett; P Silva; S Martinez; V A Torres; A F G Quest
Journal:  Curr Mol Med       Date:  2018       Impact factor: 2.222

8.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

9.  Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.

Authors:  Masatoshi Kudo; Ann-Lii Cheng; Joong-Won Park; Jae Hyung Park; Po-Chin Liang; Hisashi Hidaka; Namiki Izumi; Jeong Heo; Youn Jae Lee; I-Shyan Sheen; Chang-Fang Chiu; Hitoshi Arioka; Satoshi Morita; Yasuaki Arai
Journal:  Lancet Gastroenterol Hepatol       Date:  2017-10-04

10.  Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.

Authors:  Masatoshi Kudo; Kazuomi Ueshima; Masafumi Ikeda; Takuji Torimura; Nobukazu Tanabe; Hiroshi Aikata; Namiki Izumi; Takahiro Yamasaki; Shunsuke Nojiri; Keisuke Hino; Hidetaka Tsumura; Teiji Kuzuya; Norio Isoda; Kohichiroh Yasui; Hajime Aino; Akio Ido; Naoto Kawabe; Kazuhiko Nakao; Yoshiyuki Wada; Osamu Yokosuka; Kenichi Yoshimura; Takuji Okusaka; Junji Furuse; Norihiro Kokudo; Kiwamu Okita; Philip James Johnson; Yasuaki Arai
Journal:  Gut       Date:  2019-12-04       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.